These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33603979)

  • 21. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.
    Stockman BJ; Kothe M; Kohls D; Weibley L; Connolly BJ; Sheils AL; Cao Q; Cheng AC; Yang L; Kamath AV; Ding YH; Charlton ME
    Chem Biol Drug Des; 2009 Feb; 73(2):179-88. PubMed ID: 19207420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Druggable Allosteric Sites in β-Propeller Lectins.
    Shanina E; Kuhaudomlarp S; Lal K; Seeberger PH; Imberty A; Rademacher C
    Angew Chem Int Ed Engl; 2022 Jan; 61(1):e202109339. PubMed ID: 34713573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.
    Gao Y; Maria A; Na N; da Cruz Paula A; Gorelick AN; Hechtman JF; Carson J; Lefkowitz RA; Weigelt B; Taylor BS; Zhao H; Reis-Filho JS; de Stanchina E; Rosen N; Yao Z; Yaeger R
    Cancer Discov; 2019 Sep; 9(9):1182-1191. PubMed ID: 31227518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.
    Mittal L; Tonk RK; Awasthi A; Asthana S
    Comput Biol Chem; 2023 Dec; 107():107965. PubMed ID: 37826990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the Natural Compounds in Flavonoids for Their Potential Inhibition of Cancer Therapeutic Target MEK1 Using Computational Methods.
    AlZahrani WM; AlGhamdi SA; Zughaibi TA; Rehan M
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards the development of chromone-based MEK1/2 modulators.
    Redwan IN; Dyrager C; Solano C; Fernández de Trocóniz G; Voisin L; Bliman D; Meloche S; Grøtli M
    Eur J Med Chem; 2014 Oct; 85():127-38. PubMed ID: 25078316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric small-molecule kinase inhibitors.
    Wu P; Clausen MH; Nielsen TE
    Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
    Yari H; Ganjalikhany MR; Sadegh H
    Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Fluorescent Ligand for the Intracellular Allosteric Binding Site of the Neurotensin Receptor 1.
    Vogt H; Shinkwin P; Huber ME; Staffen N; Hübner H; Gmeiner P; Schiedel M; Weikert D
    ACS Pharmacol Transl Sci; 2024 May; 7(5):1533-1545. PubMed ID: 38751637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice.
    Faber EB; Wang N; John K; Sun L; Wong HL; Burban D; Francis R; Tian D; Hong KH; Yang A; Wang L; Elsaid M; Khalid H; Levinson NM; Schönbrunn E; Hawkinson JE; Georg GI
    J Med Chem; 2023 Feb; 66(3):1928-1940. PubMed ID: 36701569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
    Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
    Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fragment-based lead discovery to identify novel inhibitors that target the ATP binding site of pyruvate dehydrogenase kinases.
    Akaki T; Bessho Y; Ito T; Fujioka S; Ubukata M; Mori G; Yamanaka K; Orita T; Doi S; Iwanaga T; Ikegashira K; Hantani Y; Nakanishi I; Adachi T
    Bioorg Med Chem; 2021 Aug; 44():116283. PubMed ID: 34274549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New small-molecule inhibitors of mitogen-activated protein kinase kinase.
    Spicer JA
    Expert Opin Drug Discov; 2008 Jul; 3(7):801-17. PubMed ID: 23496222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1.
    Xu X; Chen Y; Fu Q; Ni D; Zhang J; Li X; Lu S
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):361-374. PubMed ID: 30734603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.
    Mingione VR; Foda ZH; Paung Y; Philipose H; Rangwala AM; Shan Y; Seeliger MA
    J Mol Biol; 2022 Sep; 434(17):167628. PubMed ID: 35595169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.
    Sheth PR; Liu Y; Hesson T; Zhao J; Vilenchik L; Liu YH; Mayhood TW; Le HV
    Biochemistry; 2011 Sep; 50(37):7964-76. PubMed ID: 21793567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel approach to the discovery of small-molecule ligands of CDK2.
    Martin MP; Alam R; Betzi S; Ingles DJ; Zhu JY; Schönbrunn E
    Chembiochem; 2012 Sep; 13(14):2128-36. PubMed ID: 22893598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.